Transition Therapeutics is a biopharmaceutical company developing novel therapeutics for disease indications with large markets.
Transition is a biopharmaceutical company, developing novel therapeutics for disease indications with large markets. Transition's lead products include ELND005 for the treatment of Alzheimer's disease and TT223 for the treatment of diabetes. Transition has an emerging pipeline of preclinical drug candidates acquired externally and developed internally using its proprietary drug discovery engine.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jun 6, 2014 | Post-IPO Equity | $30.80M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Jack W. Schuler Living Trust | — | Post-IPO Equity |